Menopausal hormone therapy in women with CADASIL: a health system-wide retrospective cross-sectional study
Many CADASIL patients experiencing menopause symptoms did not receive HT. About one-fourth of women received HT, most commonly with non-oral formulations. Transdermal and vaginal formulations and other non-hormonal medications used to treat vasomotor symptoms may be safer than oral HT for women with CADASIL.
Authors
- Roaa Zayat (ORCID: https://orcid.org/0009-0007-7026-2099)
- Md Manjurul Islam Shourav (ORCID: https://orcid.org/0000-0003-4340-3849)
- James F. Meschia (ORCID: https://orcid.org/0000-0002-4475-8142)
- Kevin M. Barrett (ORCID: https://orcid.org/0009-0005-2912-5821)
- Zhongwei Peng (ORCID: https://orcid.org/0000-0001-9342-4168)
- Michelle Lin (ORCID: https://orcid.org/0000-0002-0219-027X)
- Olga Fermo (ORCID: https://orcid.org/0000-0001-7363-4766)
- Stephanie S. Faubion (ORCID: https://orcid.org/0000-0001-9341-7726)
- Michele Caruso (ORCID: https://orcid.org/0009-0004-0773-7133)
- Dinith Mendis
Institutions
- Jacksonville College (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Journal of Stroke and Cerebrovascular Diseases
- Published
- 2025-03-16
- DOI
- https://doi.org/10.1016/j.jstrokecerebrovasdis.2025.108284
- Primary Topic
- Cerebrovascular and genetic disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00